Jiangbo Pharmaceuticals, Inc.(fka JGBO)

[Long-vestor]

A few highlights of the conference call..

Company plans increased exposure which will increase the share price, and lower the possibility of a reverse split to up-list..

The company has not made a decision as to exactly which market to up-list into.. AMEX is a likely candidate, although all markets are within consideration..

The float is estimated to be 1/4 the outstanding shares, but will provide a detailed share structure soon..

The Revenues expected this year ending June 2008 are over 100 million and 26 million in operating expenses.

Next years forecast of Baobaole Chewable Tablets revenues are in the range of 26 million. This past sales of this were in the range of 15 million. Future 2009 etc. sales are expected to rise.

There are a few new products expected to be approved soon and released in 2008..

Did not have to much chance to take notes so mostly information from memory.. Please to add or correct any mistakes I may or may not have made. tks